• Surginex

  Participated · Equity · Mar 2024

  Seojinex develops lipid nanoparticle (LNP) delivery technologies based on biodegradable ionizable lipids similar to those used in Pfizer and Moderna vaccines. The company says it has secured an LNP pipeline and claims a next‑generation, 4th‑generation targeted ionizable‑lipid LNP capable of organ targeting. Seojinex has added Ewha Womans University pharmacy professor Lee Hyuk‑jin as CTO and vice‑president to boost commercialization and technical leadership. It is pursuing partnerships with domestic and international gene‑ and cell‑therapy developers to apply its LNPs across multiple therapeutic areas. The company plans to establish large‑scale production processes and to pursue global licensing deals to commercialize its LNP platform. Since founding in September 2020, Seojinex has raised a total of ₩12.5 billion to date.

• BIORCHESTRA

  Participated · Series C · Feb 2022

  Biorchestra is an RNA therapeutics company based in Daejeon, South Korea, and Cambridge, Massachusetts. It develops RNA-based therapeutics using a BMD platform that can control microRNAs which regulate multiple messenger RNAs involved in disease. The company has developed a proprietary drug delivery system (BDDS™) for commercial drug development and reports IV-delivered ASO knock-down efficacy in cortex, hippocampus, striatum and spinal cord. Leadership includes CEO Branden (Jinhyeob) Ryu, CMO and US President Dr. Louis O’Dea, and CFO Young-Gil Kim. Biorchestra plans to use new funding to expand R&D and its product pipeline, complete a GMP facility, and initiate nonclinical toxicology programs. The company raised $45M in Series C financing to support these activities.

No current team members are available.